| 生物活性 | Capmatinib (INC280; INCB28060) is a potent, orally active, selective, and ATP competitivec-Metkinase inhibitor (IC50=0.13 nM). Capmatinib can inhibit phosphorylation of c-MET as well as c-MET pathway downstream effectors such as ERK1/2,AKT,FAK, GAB1, and STAT3/5. Capmatinib potently inhibits c-MET-dependent tumor cell proliferation and migration and effectively inducesapoptosis. Antitumor activity. Capmatinib is largely metabolized by CYP3A4 and aldehyde oxidase[1][2][3]. |
| IC50& Target | |
体外研究
(In Vitro) | Capmatinib (INCB28060) inhibits c-MET phosphorylation with an IC50value of approximately 1 nM and a concentration of approximately 4 nM inhibits c-MET more than 90%, which is reversible and the effect is significantly reduced in several hours after the compound is removed and completely disappeared by 48 hours[1].
Capmatinib (INCB28060) (0-10000 nM; 72 h) inhibits the proliferation of SNU-5, S114, H441 and U-87MG[1].
Capmatinib (INCB28060) (0.06-62.25 nM; 2h) effectively inhibits phosphorylation of c-MET as well as c-MET pathway downstream effectors such as ERK1/2, AKT, FAK, GAB1, and STAT3/5[1].
Capmatinib (INCB28060) (0.24-63 nM; over night) prevents HGF-stimulated H441 cell migration[1].
Capmatinib (INCB28060) (0.5-50 nM; 20 min) suppresses phosphorylation of both EGFR and HER-3 rapidly[1].
Capmatinib (INCB28060) (0-333 nM; 24 h) induces apoptosis in SNU-5 cells[1].
Cell Viability Assay[1] | Cell Line: | SNU-5, S114, H441 and U-87MG | | Concentration: | 0-10000 nM | | Incubation Time: | 72 h | | Result: | Inhibited the cell viability of SNU-5 and S114, as well as the colony formation of H441 and U-87MG, with IC50values of 1.2 nM, 12.4 nM, ~0.5 nM and 2 nM, respectively. |
Cell Migration Assay[1] | Cell Line: | H441 (stimulated with 50 ng/mL recombinant human HGF for 24h) | | Concentration: | 0.24, 1, 4, 16 and 63 nM | | Incubation Time: | Over night | | Result: | Prevented HGF-stimulated H441 cell migration, with IC50of approximately 2 nM, and less cell migration at 16 nM. |
Western Blot Analysis[1] | Cell Line: | SNU-5 | | Concentration: | 0.06, 0.24, 0.98, 3.91, 15.63 and 62.25 nM | | Incubation Time: | 2 h | | Result: | Effectively inhibited phosphorylation of c-MET as well as c-MET pathway downstream effectors such as ERK1/2, AKT, FAK, GAB1, and STAT3/5. |
Western Blot Analysis[1] | Cell Line: | H1993 cells | | Concentration: | 0.5, 5 and 50 nM | | Incubation Time: | 20 min | | Result: | Suppressed phosphorylation of both EGFR and HER-3 rapidly and as effectively as the compound inhibited c-MET phosphorylation in H1993 cells. |
Apoptosis Analysis[1] | Cell Line: | SNU-5 cells | | Concentration: | 0.017, 0.15, 1.37, 12.33, 111 and 333 nM | | Incubation Time: | 24 h | | Result: | Effectively induced DNA fragmentation. |
|
体内研究
(In Vivo) | Capmatinib (INCB28060) (1-30 mg/kg; PO, twice daily, for 2 weeks) exhibits dose-dependent inhibition of tumor growth, and shows well tolerance at all doses during the treatment periods, with no evidence of overt toxicity or weight loss in U-87MG tumor mice model[1].
Capmatinib (INCB28060) (0.03-10 mg/kg; PO, single dosage) causes inhibition of c-MET phosphorylation in S114 tumor mice model[1].
| Animal Model: | Female Balb/c nu/nu mice (inoculated subcutaneously with 5×106U-87MG glioblastoma cells)[1] | | Dosage: | 1, 3, 10 and 30 mg/kg | | Administration: | PO, twice daily, for 2 weeks | | Result: | Exhibited dose-dependent inhibition of tumor growth with 35% and 76% at 1 and 3 mg/kg once daily; resulted in partial regressions in 6 of 10 U-87MG tumor-bearing mice at 10 mg/kg once daily; and showed well tolerance at all doses during the treatment periods, with no evidence of overt toxicity or weight loss. |
| Animal Model: | Female Balb/c nu/nu mice (inoculated subcutaneously with 4×106S114 tumor cells)[1] | | Dosage: | 0.03, 0.1, 0.3, 1, 3 and 10 mg/kg | | Administration: | PO, single dosage | | Result: | Caused approximately 50% and 90% inhibition of c-MET phosphorylation at 0.03 and 0.3 mg/kg after administration of 30 min, and inhibition of phospho-c-MET exceeded 90% after 7 hours. |
|
| Clinical Trial | |
| 分子量 | |
| 性状 | |
| Formula | |
| CAS 号 | |
| 中文名称 | |
| 运输条件 | Room temperature in continental US; may vary elsewhere. |
| 储存方式 | | Powder | -20°C | 3 years | | 4°C | 2 years | | In solvent | -80°C | 6 months | | -20°C | 1 month |
|
| 溶解性数据 | In Vitro: DMSO : 25 mg/mL(60.62 mM;Need ultrasonic) H2O : 4 mg/mL(9.70 mM;Need ultrasonic) 配制储备液 | 1 mM | 2.4247 mL | 12.1236 mL | 24.2471 mL | | 5 mM | 0.4849 mL | 2.4247 mL | 4.8494 mL | | 10 mM | 0.2425 mL | 1.2124 mL | 2.4247 mL |
*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80℃, 6 months; -20℃, 1 month。-80℃ 储存时，请在 6 个月内使用，-20℃ 储存时，请在 1 个月内使用。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液，再依次添加助溶剂： ——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；
以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶 1. 请依序添加每种溶剂： 10% DMSO 40%PEG300 5%Tween-80 45% saline Solubility: ≥ 2.08 mg/mL (5.04 mM); Clear solution
此方案可获得 ≥ 2.08 mg/mL (5.04 mM，饱和度未知) 的澄清溶液。 以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。 2. 请依序添加每种溶剂： 10% DMSO 90% (20%SBE-β-CDin saline) Solubility: ≥ 2.08 mg/mL (5.04 mM); Clear solution
此方案可获得 ≥ 2.08 mg/mL (5.04 mM，饱和度未知) 的澄清溶液。 以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。 *以上所有助溶剂都可在本网站选购。
|
